211:. The board issued its disciplinary action against Potti but imposed no sanctions. In its consent order, the North Carolina Medical Board stated that the board has no evidence from which it could conclude that Potti received funding for medical research as a result of the inaccuracies that he would not have otherwise received, but concluded that "...Potti's conduct as described herein constitutes unprofessional conduct..." In separate action on Potti's medical license, the North Carolina Medical Board reviewed 11 payments made to settle malpractice claims and posted on its website that "no public action was warranted". Potti was issued a medical license in Missouri on 1 February 2011; on 6 March 2012, the Missouri medical board (known as the Board of Registration for the Healing Arts) issued a reprimand on the basis of actions taken by the North Carolina Medical Board.
279:
recommendations released in March 2012 spoke to the many parties responsible for discovery and development of omics-based tests, including investigators, their institutions, sponsors of research, the FDA, and journals. The report identified best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials. The IOM's recommendations aimed to ensure that progress in omics test development is grounded in sound scientific practice and is reproducible, resulting not only in improved health care but also in continued public trust.
283:
called for scientific investigators to make the data, computer codes and computational procedures used to develop their clinical tests "publicly accessible for independent review" and to ensure that their data and research steps are presented comprehensibly. The report also found that so-called "omics" tests – such as genomics and proteomics, which are diagnostic tools based on molecular patterns – are in general highly prone to errors. IOM committee chair
Gilbert Omenn, a computational biologist at the University of Michigan, said the problems could have been avoided. But he noted, as well, that those kinds of problems were not unique to Duke. "There are a lot of lessons here that surely apply to other places," Omenn said.
378:. Venous thromboembolism (VTE) affects about 3 in 1000 Americans. Out of the three, 10% have aPLAs. This study consisted of 129 patients. Out of those 129, 57 had APS and VTE, 32 had VTE without aPLA, 32 had aPLA, and 8 were healthy. Gene-expression profiles identify and predict individuals with APS from patients with VTE without aPLA. It is important to be able to predict APS and venous thrombosis because it will help with the management of the disease. This article was retracted because the other authors were unable to reproduce the data Potti cited.
204:(USFDA) reviewed one of the studies in 2009, several years after its initiation, and concluded that the study would require an Investigational New Drug application, which had not been submitted. An FDA audit in 2011 further showed that an Investigational Device Exemption application had not been filed, but otherwise found "no significant deficiencies" in Duke's IRB conduct. Potti's medical license record with the North Carolina Medical Board shows eleven settlements, each of at least $ 75,000, for incidents that appear to be related to these trials.
2651:
2593:
38:(ORI) found that Potti had engaged in research misconduct. According to Potti's voluntary settlement agreement with ORI, Potti can continue to perform research with the requirement of supervision until year 2020, while he "neither admits nor denies ORI's findings of research misconduct." As of 2024 Potti, who is employed at the Cancer Center of North Dakota, has had 11 of his research publications retracted, one publication has received an expression of concern, and two others have been corrected.
306:. They also can help predict how a person will respond to treatment and improve prognosis. The authors said they wanted to retract this article because "…we have been unable to reproduce certain key experiments described in the paper regarding validation and use of the colon cancer prognostic signature. This includes the validation performed with dataset E-MEXP-1224, as reported in Fig. 2A, as well as the generation of prognostic scores for colon cancer cell lines, as reported in Fig. 4…"
402:. It is important for cancer patients to receive the most effective treatment while also hopefully having the best quality of life possible. The researchers developed mRNA and microRNA profiles. They tested the mRNA profiles on 133 breast cancer patients. These breast cancer patients had been treated with TFAC chemotherapy treatment. This article was retracted as some of the information used in it derived from the
180:'s report, entitled "Evolution of Translational Omics: Lessons Learned and the Path Forward", was published on 23 March 2012 and made detailed specific recommendations for clinical trials that incorporate "omics". In February 2012, Joseph Nevins stated that it was "abundantly clear" that there was "manipulated data" that could not have occurred by chance. This was confirmed by the 2015 ORI report.
390:. The patients of this study were in stage IB, II, or IIIA of non-small cell lung cancer. Many patients receive surgery, but the risk of relapse is high. Others receive toxic chemotherapy unnecessarily. This study used gene-expressions to evaluate what form of treatment would be best. This article was retracted by the authors because they could not reproduce the results from the article.
348:). The patients had early-stage breast carcinoma. The study's main point was to find if gene expression signatures could refine breast cancer prognosis. This article talks about cancer, genomic technology, and chemotherapy and radiation. This article was retracted because a large part of the article was based on another article that Potti had written and had published in
334:. Gene expression signatures were developed with in vitro drug sensitivity data and Affymetrix microarray data. These were used to help predict response and sensitivity to chemotherapeutic drugs as well as corresponding drugs. This article was retracted after being corrected because many key experiments could not be reproduced.
159:
Duke
University became aware of the suspicions of research misconduct by 2008, when a medical student working with Potti and Nevins withdrew his name from the research and submitted a memorandum entitled "Research Concerns" to the administration. The administration denied any misconduct and convinced
278:
Following questions raised about genomics research that was led by Potti and Nevins at Duke between 2004 and 2010, the
National Cancer Institute requested that the Institute of Medicine (IOM) establish a committee to recommend ways to strengthen omics-based test development and evaluation. The IOM's
225:
In addition to the settlements, two lawsuits also have been filed against Potti, as well as against Duke and other medical personnel there, charging medical negligence among other claims. In his response to the lawsuits, Potti stated that he was "not aware that false or improper data was included in
368:. Usually, platinum-based chemotherapy is used to treat non-small cell lung cancer, but how patients respond is highly variable. This article also talks about predicting how individuals will respond to cisplatin and pemetrexed. This article was retracted because experiments could not be reproduced.
282:
The IOM report further added that "failure by many parties to detect or act on problems with key data and computational methods … led to the inappropriate enrollment of patients in clinical trials, premature launch of companies and retraction of dozens of research papers." The report specifically
2752:
Stevenson, Marvaretta; Mostertz, William; Acharya, Chaitanya; Kim, William; Walters, Kelli; Barry, William; Higgins, Kristin; Tuchman, Sascha A.; Crawford, Jeffrey; Vlahovic, Gordana; Ready, Neal; Onaitis, Mark; Potti, Anil (2009). "Characterizing the
Clinical Relevance of an Embryonic Stem Cell
2167:
Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A (1 October 2007). "Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced
427:
on 15 December 2009. The study purportedly found a common gene expression pattern between lung adenocarcinomas and normal human embryonic stem cells that was associated with a shorter survival of patients with the lung cancer. On 21 February 2012, the manuscript was retracted. The retraction
2813:
Stevenson, M.; Mostertz, W.; Acharya, C. R.; Kim, W.; Walters, K.; Barry, W.; Higgins, K.; Tuchman, S. A.; Crawford, J.; Vlahovic, G.; Ready, N.; Onaitis, M.; Potti, A. (2012). "Retraction: Characterizing the
Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma".
428:
statement was signed by all authors and indicated "that clinical information from a data set ... available at the time of the signature development, was incorrect". Further, that statement indicated that "Drs. Anil Potti and
Marvaretta Stevenson take full responsibility for this error".
320:. The researchers wanted to confirm their previous studies of gene-expression signatures in predicting the effects of chemotherapeutic drugs. The article was retracted because the validity of the results was beginning to be questioned and because predictions were made off of the
461:). This study, conducted at Duke University from July 2008 until June 2009, investigated age and gender influence on response to cancer by studying the genes of 787 non-small cell lung cancer patients. The article is under review but has not been retracted as of February 2012.
2120:
Acharya, C. R.; Hsu, D. S.; Anders, C. K.; Anguiano, A.; Salter, K. H.; Walters, K. S.; Redman, R. C.; Tuchman, S. A.; Moylan, C. A.; Mukherjee, S.; Barry, W. T.; Dressman, H. K.; Ginsburg, G. S.; Marcom, K. P.; Garman, K. S.; Lyman, G. H.; Nevins, J. R.; Potti, A. (2012).
2391:
Potti, Anil; Mukherjee, Sayan; Petersen, Rebecca; Dressman, Holly K.; Bild, Andrea; Koontz, Jason; Kratzke, Robert; Watson, Mark A.; Kelley, Michael; Ginsburg, Geoffrey S.; West, Mike; Harpole, David H.; Nevins, Joseph R. (10 August 2006).
2059:
Acharya, CR; Hsu, DS; Anders, CK; Anguiano, A; Salter, KH; Walters, KS; Redman, RC; Tuchman, SA; Moylan, CA (2 April 2008). "Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer".
69:
Potti resigned from Duke in 2010, following the discovery of flaws in the genomics research conducted at Duke and allegations of embellishments in his resume, assuming responsibility for the anomalies in the scientific research.
1565:
192:
stopped payments of a five-year grant which totaled $ 729,000 as Potti had received the grant based on his credentials. Duke
University later reimbursed the American Cancer Society for the full amount of the grant.
416:
in
February 2007. The research studied ovarian cancer patient responses to platinum-based therapy. This marks the latest in a series of about 13 expected Potti retractions, with another 13 expected partial
51:
2898:
Mostertz, W; Stevenson, M; Acharya, C; Chan, I; Walters, K; Lamlertthon, W; Barry, W; Crawford, J; Nevins, J (10 February 2010). "Age- and Sex-Specific
Genomic Profiles in Non-Small Cell Lung Cancer".
1783:
Mostertz, W; Stevenson, M; Acharya, C; Chan, I; Walters, K; Lamlertthon, W; Barry, W; Crawford, J; Nevins, J (10 February 2010). "Age- and sex-specific genomic profiles in non-small cell lung cancer".
2606:
Salter, Kelly H.; Acharya, Chaitanya R.; Walters, Kelli S.; Redman, Richard; Anguiano, Ariel; Garman, Katherine S.; Anders, Carey K.; Mukherjee, Sayan; Dressman, Holly K. (2011). Ouchi, Toru (ed.).
270:, provider of the WordPress webhost service that hosts Retraction Watch, filed suit against the filer of the takedown notice, saying that he had made those false claims in violation of the DMCA.
2997:
120:
that he had been a "Rhodes
Scholar (Australian Board)". He said he was referring to the Association of Rhodes Scholars in Australia Scholarships, an award granted by an organisation of former
1377:
1718:
440:, this paper was retracted in 2012 with the retraction notice stating, "The authors relied on the results reported by Potti, and they were not aware of the errors subsequently reported."
2849:"Notice of Retraction: Upregulated Oncogenic Pathways in Patients Exposed to Tobacco Smoke May Provide a Novel Approach to Lung Cancer Chemoprevention (Chest. 2008;134:158001S)".
1569:
1462:
1282:
2583:
1341:
1268:
2513:
Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A (2 April 2008).
1910:
Bonnefoi, Hervé; Potti, Anil; Delorenzi, Mauro; Mauriac, Louis; Campone, Mario; Tubiana-Hulin, Michèle; Petit, Thierry; Rouanet, Philippe; Jassem, Jacek (December 2007).
897:
2992:
1978:"Retraction validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial"
1912:"RETRACTED: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: A substudy of the EORTC 10994/BIG 00-01 clinical trial"
2229:"Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350–7, 2007"
2499:
1434:
266:
blog posts critical of Potti and the posts were removed. Retraction Watch alleges that these DMCA take-down notices were based on false claims. In November 2013,
93:. He resigned in November 2010 after Duke put him on administrative leave, terminated the clinical trials based on his research and retracted his published data.
1976:
Bonnefoi, Hervé; Potti, Anil; Delorenzi, Mauro; Mauriac, Louis; Campone, Mario; Tubiana-Hulin, Michèle; Petit, Thierry; Rouanet, Philippe; Jassem, Jacek (2011).
2458:
Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR (24 March 2011).
1543:
2018:
Potti, Anil; Dressman, Holly K; Bild, Andrea; Riedel, Richard F; Chan, Gina; Sayer, Robyn; Cragun, Janiel; Cottrill, Hope; Kelley, Michael J (January 2011).
1005:
911:
1381:
679:
236:
reported this as "The fallout from the Duke case includes 27 papers that Duke expects to be partially or completely retracted". As of February 2012, ten
1663:
1513:
2972:
544:
132:
1363:
708:
1755:
1591:
471:
1769:
1635:
511:
200:
based on Potti's research came under scrutiny in 2009 and were temporarily suspended, then were permanently stopped in 2010. The United States
1649:
1977:
1693:
1056:
2987:
1613:
814:
1960:
232:
of Duke testified that they had looked at 40 of Potti's publications and that two-thirds of them would be retracted in whole or in part.
1826:
Garman, K. S.; Acharya, C. R.; Edelman, E.; Grade, M.; Gaedcke, J.; Sud, S.; Barry, W.; Diehl, A. M.; Provenzale, D. (2 December 2008).
1476:
2736:
2876:
2123:"Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer"
1297:
241:
90:
1448:
291:
As of 2018, 11 papers co-authored by Potti have been retracted, and seven others have been corrected. Potti's retracted papers are:
47:
2967:
951:
585:
431:"Upregulated Oncogenic Pathways in Patients Exposed to Tobacco Smoke May Provide a Novel Approach to Lung Cancer Chemoprevention"
386:
161:
140:
359:"Pharmacogenomic Strategies Provide a Rational Approach to the Treatment of Cisplatin-Resistant Patients with Advanced Cancer"
1499:
197:
2460:"Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570–80"
492:
1751:
128:
2982:
1417:
364:
201:
82:
35:
2686:
Dressman, H.K.; Berchuck, A.; Chan, G.; Zhai, J.; Bild, A.; Sayer, R.; Craygun, J.; Clarke, J.; Whitaker, R.S. (2007).
1094:
726:
406:
article which had been retracted. As that article had been retracted, it was felt that this article should be, as well.
2962:
2104:
1038:
2664:
2326:
991:
937:
302:. Gene expressions could allow the researchers to see if tumors are uniform throughout. This could also be used with
188:
Healthcare companies cut ties with Potti after evidence surfaced that Potti had fabricated awards on his resume. The
1169:
898:"Potti letter addresses scandal: Former researcher calls Rhodes controversy a misunderstanding | The Chronicle"
683:
2977:
2957:
2608:"Retraction: An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer"
1109:
769:
2797:
2688:"An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer"
1894:
915:
626:
409:"An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer"
218:, which was approved in April 2011. Potti was employed as a practicing physician at the Coastal Cancer Center in
136:
109:
1828:"A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities"
1342:"Anil Potti reprimanded by North Carolina state medical board, as lawsuit settlements surface "Retraction Watch"
846:
648:
295:"A Genomic Approach to Colon Cancer Risk Stratification Yields Biologic Insights into Therapeutic Opportunities"
2624:
2571:
875:
73:
Following his resignation from Duke, Potti worked as an oncologist in South Carolina, but was let go in 2012.
1671:
189:
112:, 2010 brought further and more widespread scrutiny when it was discovered by Paul Goldberg and reported in
2650:
2592:
2952:
1236:
2493:
2442:
2212:
1746:
1744:
1742:
1740:
1738:
1736:
977:
248:
219:
177:
173:
86:
337:"Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer"
2515:"An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer"
393:"An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer"
309:"Validation of Gene Signatures that Predict the Response of Breast Cancer to Neoadjuvant Chemotherapy"
2947:
2528:
2122:
1839:
1200:
259:
1514:"Updated: Anil Potti out at Coastal Cancer Center; practice blames Duke for glowing recommendations"
1144:
744:
703:
701:
521:
101:
788:
420:"Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma"
2923:
1808:
1719:"Wordpress Goes Legal: Sues Over Two Egregiously Bogus DMCA Notices That Were Designed To Censor"
1125:
1435:"Troubles continue for former Duke oncologist (Charleston Post and Courier, 23 February, 20120)"
100:
genetic analysis for personalised cancer treatment, which was published in various prestigious
2915:
2831:
2789:
2770:
2728:
2709:
2639:
2575:
2556:
2481:
2434:
2415:
2373:
2318:
2299:
2250:
2204:
2185:
2142:
2096:
2077:
2041:
1997:
1952:
1933:
1886:
1867:
1800:
1456:
1276:
1218:
1062:
1052:
1040:
Evolution of Translational Omics: Lessons Learned and the Path Forward – Institute of Medicine
237:
113:
2907:
2858:
2823:
2781:
2762:
2720:
2699:
2629:
2619:
2567:
2546:
2536:
2471:
2426:
2405:
2363:
2355:
2310:
2289:
2281:
2240:
2196:
2177:
2134:
2088:
2069:
2031:
1989:
1944:
1923:
1878:
1857:
1847:
1792:
1254:
1208:
1117:
1044:
263:
164:. Duke later falsely claimed that there had not been a whistleblower involved in the issue.
117:
436:
208:
63:
31:
23:
104:. While there were questions concerning Potti's work beginning in 2007, notably from two
2532:
1843:
1204:
815:"Houston docs found leak in Holy Grail of cancer treatment. Houston Chronicle, 2/18/12)"
2634:
2607:
2551:
2514:
2368:
2344:"Retraction. Gene-expression patterns predict phenotypes of immune-mediated thrombosis"
2343:
2294:
2269:
1862:
1827:
1006:"Duke University officials rebuffed medical student's allegations of research problems"
215:
121:
97:
30:. He, along with Joseph Nevins, are at the center of a research fabrication scandal at
1993:
1948:
1928:
1911:
1319:
955:
2941:
1129:
833:"Prominent Duke Scientist Claimed Prizes He Didn't Win, Including Rhodes Scholarship"
549:
317:
229:
105:
2927:
1812:
207:
In late 2011, the North Carolina Medical Board reprimanded Potti but he retains his
2268:
Potti, A; Bild, A; Dressman, HK; Lewis, DA; Nevins, JR; Ortel, TL (February 2006).
1636:"Anil Potti and colleagues retract ninth paper, this one in JCO " Retraction Watch"
493:"60 Minutes to delve into Potti case (Triangle Business Journal, February 10, 2012"
303:
27:
2827:
2785:
2766:
2394:"A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer"
381:"A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer"
2541:
2359:
2314:
1770:"Anil Potti resurfaces with job at North Dakota cancer center – Retraction Watch"
124:
to bring Commonwealth citizens who attend overseas institutions in to Australia.
1697:
1650:"Tenth Potti retraction appears, in Clinical Cancer Research " Retraction Watch"
847:"Duke scientist Anil Potti's different CVs: version 1, version 2, and version 3"
50:, Vellore, India in 1995. He finished an internship in Internal Medicine at the
2342:
Potti A, Bild A, Dressman HK, Lewis DA, Nevins JR, Ortel TL (20 October 2011).
2285:
1832:
Proceedings of the National Academy of Sciences of the United States of America
1110:"Lapses in oversight compromise omics results : Nature News & Comment"
1121:
832:
267:
147:
55:
2724:
2704:
2687:
2245:
2228:
2200:
2181:
2073:
1418:"Potti reprimanded by Missouri medical board (The Chronicle, March 12, 2012)"
1882:
1852:
600:
255:
2919:
2835:
2793:
2774:
2732:
2713:
2643:
2579:
2560:
2485:
2438:
2419:
2377:
2322:
2303:
2270:"Gene-expression patterns predict phenotypes of immune-mediated thrombosis"
2254:
2208:
2189:
2146:
2100:
2081:
2045:
2001:
1956:
1937:
1890:
1871:
1804:
1298:"Payouts mount for ex-Duke doc for malpractice – Triangle Business Journal"
1222:
1066:
371:"Gene-expression Patterns Predict Phenotypes of Immune-mediated Thrombosis"
2862:
2911:
2519:
2476:
2459:
2430:
2410:
2393:
1796:
1477:"Anil Potti resurfaces at South Carolina cancer center "Retraction Watch"
1019:
952:"Case Summary: Potti, Anil | ORI - the Office of Research Integrity"
555:
516:
398:
176:
to conduct a study of the proper use of genomics in clinical trials. The
151:
described the case as "one of the biggest medical research frauds ever".
59:
2138:
2092:
1752:"Evolution of Translational Omics: Lessons Learned and the Path Forward"
1451:. Coastal Cancer Center. Archived from the original on 16 February 2012.
938:"Ninth Potti paper to date gets retracted – Duke Chronicle, Feb 7, 2012"
127:
Potti's fraudulent research was funded by the US government through the
96:
Potti and his team were accused of falsifying data regarding the use of
2036:
2019:
89:
while a cancer researcher at both Duke University's Medical Center and
2020:"Retraction: Genomic signatures to guide the use of chemotherapeutics"
450:"Age- and Sex-Specific Genomic Profiles in Non-Small Cell Lung Cancer"
1535:
1037:
Micheel, Christine M; Nass, Sharly J; Omenn, Gilbert S, eds. (2012).
709:""Anil Potti, Duke Cancer Researcher Accused of Misconduct, Resigns""
1694:"Site plagiarizes blog posts, then files DMCA takedown on originals"
1592:"New in PNAS: Potti retraction number seven, and a Potti correction"
1213:
1188:
850:
1403:
1048:
2013:
2011:
160:
the student not to report his experiences to the funding agency,
1614:"Potti and colleagues retract 2008 JAMA paper "Retraction Watch"
2877:"Another retraction for Anil Potti, with an inscrutable notice"
1364:"Tainted doctor working in S.C. (Charleston Post and Courier)"
978:"Universities stonewall investigations of research misconduct"
674:
672:
670:
531:
316:
This study involved patients with oestrogen-receptor-negative
274:
Research questions and Institute of Medicine report on 'Omics'
1145:"Duke Scientist Suspended Over Rhodes Scholar Claims.%7C2010"
247:
After leaving Duke, Potti hired Online Reputation Manager, a
1271:. NBC17.com. Archived from the original on 14 February 2012.
222:
from March 2011 until 21 February 2012, when he was let go.
356:
had been retracted because of failure to reproduce results.
586:"Federal Register :: Findings of Research Misconduct"
327:"Genomic Signatures to Guide the Use of Chemotherapeutics"
1088:
1086:
1084:
1082:
1080:
1078:
1076:
1566:"Second lawsuit filed against Duke for Potti's research"
745:"Duke Scientist Suspended Over Rhodes Scholarship Claim"
2625:
10.1371/annotation/8f94e479-4161-43a0-a28c-4c0460bb89a4
2572:
10.1371/annotation/8f94e479-4161-43a0-a28c-4c0460bb89a4
214:
In January 2011 Potti applied for a medical license in
26:
associate professor and cancer researcher, focusing on
1320:"Disgraced Duke researcher settles malpractice claims"
1095:"Panel Calls for Closer Oversight of Biomarker Tests"
727:"Panel Calls for Closer Oversight of Biomarker Tests"
506:
504:
502:
139:, in the form of six multi-year grants, and by the
108:statisticians, Keith Baggerly and Kevin Coombes at
2998:People involved in scientific misconduct incidents
1652:. Retractionwatch.wordpress.com. 22 February 2012.
554:
1638:. Retractionwatch.wordpress.com. 6 February 2012.
1516:. Retractionwatch.wordpress.com. 22 February 2012
912:"Rhodes scholars – Research Grants and Contracts"
789:"How Bright Promise in Cancer Testing Fell Apart"
251:company, to improve search results for his name.
1461:: CS1 maint: bot: original URL status unknown (
1344:. Retractionwatch.wordpress.com. 5 December 2011
1281:: CS1 maint: bot: original URL status unknown (
1269:"NBC-17 Investigates FDA findings in Duke audit"
849:. cancerletter.com. 16 July 2012. Archived from
16:Cancer scientist accused of misconduct and fraud
1594:. Retractionwatch.wordpress.com. 5 October 2011
1616:. Retractionwatch.wordpress.com. 2 April 2008
1479:. Retractionwatch.wordpress.com. 16 June 2011
1170:""Health care companies cut ties with Potti""
54:in 1999. In 2006 Potti completed training in
52:University of North Dakota School of Medicine
8:
2498:: CS1 maint: multiple names: authors list (
1500:"Cancer researcher Potti loses his S.C. job"
1404:"Board of Registration for the Healing Arts"
870:
868:
455:Journal of the American Medicine Association
2665:"Ninth Potti paper to date gets retracted"
738:
736:
545:"Misconduct in science An array of errors"
374:This article was published in the journal
2703:
2633:
2623:
2550:
2540:
2475:
2409:
2367:
2293:
2244:
2035:
1927:
1861:
1851:
1212:
914:. Research.unimelb.edu.au. Archived from
627:"The Anil Potti retraction record so far"
133:National Heart, Lung, and Blood Institute
2993:Medical controversies in the Netherlands
580:
578:
576:
574:
346:Journal of American Medicine Association
1664:"Potti hires online reputation manager"
1437:. Postandcourier.com. 22 February 2012.
1366:. Postandcourier.com. 15 February 2012.
1255:"Home – the Cancer Letter Publications"
483:
472:List of scientific misconduct incidents
240:authored by Potti and others have been
2491:
1546:from the original on 26 September 2011
1454:
1274:
770:""Suspended cancer trials terminated""
1429:
1427:
1108:Check Hayden, Erika (23 March 2012).
900:. Dukechronicle.com. 11 January 2012.
813:Kilday, Patricia (18 February 2012).
7:
2667:. Dukechronicle.com. 7 February 2012
682:. Pps.ncmedboard.org. Archived from
655:. The Center of Scientific Integrity
629:. Retraction Watch. 14 February 2012
2753:Phenotype in Lung Adenocarcinoma".
1498:Debruyn, Jason (22 February 2012).
992:"Reference at www.newsobserver.com"
553:. 10 September 2011. Archived from
491:Debruyn, Jason (10 February 2012).
2879:. Retraction Watch. 5 October 2012
1758:from the original on 22 July 2014.
384:This article was published in the
362:This article was published in the
14:
1093:Kaiser, Jocelyn (23 March 2012).
835:. cancerletter.com. 16 July 2012.
2973:Ethics of science and technology
2649:
2591:
1568:. The Herald Sun. Archived from
1536:"Duke sued over clinical trials"
1296:Debruyn, Jason (13 March 2011).
878:. Duke Chronicle. 29 August 2010
876:"Resume reveals inconsistencies"
743:Singer, Natasha (20 July 2010).
453:This paper was published in the
412:This paper was published in the
2464:New England Journal of Medicine
2398:New England Journal of Medicine
1670:. 14 April 2011. Archived from
607:. Cancer Center of North Dakota
590:Findings of Research Misconduct
387:New England Journal of Medicine
172:The Potti scandal prompted the
162:Howard Hughes Medical Institute
141:Howard Hughes Medical Institute
2239:(35): 5229. 10 December 2010.
1237:""Cancer research questioned""
1189:"Cancer trial errors revealed"
1187:Samuel Reich, Eugenie (2011).
680:"North Carolina Medical Board"
396:This article was published in
340:This article was published in
330:This article was published in
312:This article was published in
298:This article was published by
198:Duke University Medical Center
116:that Potti had claimed on his
1:
2828:10.1158/1078-0432.CCR-12-0337
2786:10.1158/1078-0432.CCR-12-0337
2767:10.1158/1078-0432.CCR-09-1939
1994:10.1016/S1470-2045(11)70011-0
1949:10.1016/S1470-2045(11)70011-0
1929:10.1016/S1470-2045(07)70345-5
605:Cancer Center of North Dakota
129:National Institutes of Health
2692:Journal of Clinical Oncology
2542:10.1371/journal.pone.0001908
2360:10.1182/blood-2011-08-375030
2315:10.1182/blood-2011-08-375030
2233:Journal of Clinical Oncology
2170:Journal of Clinical Oncology
1721:. Techdirt. 21 November 2013
1406:. Pr.mo.gov. 28 August 2011.
787:Kolata, Gina (7 July 2011).
423:This paper was published in
414:Journal of Clinical Oncology
365:Journal of Clinical Oncology
202:Food and Drug Administration
83:Office of Research Integrity
36:Office of Research Integrity
2988:Hoaxes in the United States
649:"Retraction Watch Database"
324:article that was retracted.
3014:
2286:10.1182/blood-2005-07-2669
1322:. WRAL.com. 2 January 2012
1143:Singer, N (20 July 2010).
46:Anil Potti graduated from
34:. On 9 November 2015, the
22:is a physician and former
2857:(4): 1079. October 2012.
1122:10.1038/nature.2012.10298
434:Published in the journal
196:Three clinical trials at
137:National Cancer Institute
110:MD Anderson Cancer Center
48:Christian Medical College
2816:Clinical Cancer Research
2755:Clinical Cancer Research
2725:10.1200/JCO.2012.42.0331
2705:10.1200/JCO.2006.06.3743
2246:10.1200/JCO.2010.33.7311
2201:10.1200/JCO.2010.33.7311
2182:10.1200/JCO.2007.11.0593
2074:10.1001/jama.299.13.1574
425:Clinical Cancer Research
85:(ORI), Potti engaged in
2968:Duke University faculty
1883:10.1073/pnas.1115170108
1853:10.1073/pnas.0806674105
1449:"Coastal Cancer Center"
190:American Cancer Society
1097:. News.sciencemag.org.
2863:10.1378/chest.12-1284
2780:(Retracted, see
2719:(Retracted, see
2566:(Retracted, see
2425:(Retracted, see
2309:(Retracted, see
2195:(Retracted, see
2087:(Retracted, see
1943:(Retracted, see
1877:(Retracted, see
1378:"NCMB Action Revised"
512:""Deception at Duke""
445:Paper under suspicion
260:DMCA takedown notices
249:reputation management
178:Institute of Medicine
174:Institute of Medicine
87:scientific misconduct
77:Scientific misconduct
2912:10.1001/jama.2010.80
2477:10.1056/NEJMc1101915
2431:10.1056/NEJMc1101915
2411:10.1056/NEJMoa060467
1797:10.1001/jama.2010.80
1542:. 8 September 2011.
1420:. Dukechronicle.com.
1026:. 10 September 2011.
1020:"An array of errors"
940:. Dukechronicle.com.
524:on 13 February 2012.
273:
2983:Health fraud people
2533:2008PLoSO...3.1908S
2139:10.1001/jama.2012.2
2093:10.1001/jama.2012.2
1982:The Lancet Oncology
1844:2008PNAS..10519432G
1674:on 28 February 2013
1205:2011Natur.469..139S
155:University response
102:scientific journals
2963:Cancer researchers
2037:10.1038/nm0111-135
1149:The New York Times
1008:. 12 January 2015.
918:on 13 October 2011
793:The New York Times
749:The New York Times
588:. 9 November 2015.
534:, 12 February 2012
495:. Bizjournals.com.
254:In February 2013,
91:School of Medicine
2978:Hoaxes in science
2958:Academic scandals
2761:(24): 7553–7561.
1772:. 20 August 2012.
1300:. Bizjournals.com
1199:(7329): 139–140.
1058:978-0-309-22418-5
853:on 27 August 2016
819:Houston Chronicle
352:. The article in
238:scientific papers
114:The Cancer Letter
81:According to the
3005:
2932:
2931:
2895:
2889:
2888:
2886:
2884:
2873:
2867:
2866:
2846:
2840:
2839:
2810:
2804:
2803:
2799:Retraction Watch
2778:
2749:
2743:
2742:
2738:Retraction Watch
2717:
2707:
2683:
2677:
2676:
2674:
2672:
2661:
2655:
2654:
2653:
2647:
2637:
2627:
2603:
2597:
2596:
2595:
2589:
2585:Retraction Watch
2564:
2554:
2544:
2510:
2504:
2503:
2497:
2489:
2479:
2455:
2449:
2448:
2444:Retraction Watch
2423:
2413:
2388:
2382:
2381:
2371:
2339:
2333:
2332:
2328:Retraction Watch
2307:
2297:
2265:
2259:
2258:
2248:
2225:
2219:
2218:
2214:Retraction Watch
2193:
2164:
2158:
2157:
2155:
2153:
2117:
2111:
2110:
2106:Retraction Watch
2085:
2056:
2050:
2049:
2039:
2015:
2006:
2005:
1973:
1967:
1966:
1962:Retraction Watch
1941:
1931:
1907:
1901:
1900:
1896:Retraction Watch
1875:
1865:
1855:
1838:(49): 19432–37.
1823:
1817:
1816:
1780:
1774:
1773:
1766:
1760:
1759:
1748:
1731:
1730:
1728:
1726:
1715:
1709:
1708:
1706:
1704:
1690:
1684:
1683:
1681:
1679:
1660:
1654:
1653:
1646:
1640:
1639:
1632:
1626:
1625:
1623:
1621:
1610:
1604:
1603:
1601:
1599:
1588:
1582:
1581:
1579:
1577:
1562:
1556:
1555:
1553:
1551:
1532:
1526:
1525:
1523:
1521:
1510:
1504:
1503:
1495:
1489:
1488:
1486:
1484:
1473:
1467:
1466:
1460:
1452:
1445:
1439:
1438:
1431:
1422:
1421:
1414:
1408:
1407:
1400:
1394:
1393:
1391:
1389:
1384:on 15 April 2013
1380:. Archived from
1374:
1368:
1367:
1360:
1354:
1353:
1351:
1349:
1338:
1332:
1331:
1329:
1327:
1316:
1310:
1309:
1307:
1305:
1293:
1287:
1286:
1280:
1272:
1265:
1259:
1258:
1251:
1245:
1240:
1233:
1227:
1226:
1216:
1184:
1178:
1173:
1166:
1160:
1159:
1157:
1155:
1140:
1134:
1133:
1105:
1099:
1098:
1090:
1071:
1070:
1034:
1028:
1027:
1016:
1010:
1009:
1002:
996:
995:
988:
982:
981:
974:
968:
967:
965:
963:
954:. Archived from
948:
942:
941:
934:
928:
927:
925:
923:
908:
902:
901:
894:
888:
887:
885:
883:
872:
863:
862:
860:
858:
843:
837:
836:
829:
823:
822:
810:
804:
803:
801:
799:
784:
778:
773:
766:
760:
759:
757:
755:
740:
731:
730:
729:. 23 March 2012.
723:
717:
712:
705:
696:
695:
693:
691:
686:on 15 April 2013
676:
665:
664:
662:
660:
653:Retraction Watch
645:
639:
638:
636:
634:
623:
617:
616:
614:
612:
597:
591:
589:
582:
569:
568:
566:
564:
559:on 27 April 2020
558:
541:
535:
525:
520:. Archived from
508:
497:
496:
488:
314:Lancet Oncology.
287:Retracted papers
264:Retraction Watch
118:curriculum vitae
3013:
3012:
3008:
3007:
3006:
3004:
3003:
3002:
2938:
2937:
2936:
2935:
2897:
2896:
2892:
2882:
2880:
2875:
2874:
2870:
2848:
2847:
2843:
2812:
2811:
2807:
2779:
2751:
2750:
2746:
2718:
2685:
2684:
2680:
2670:
2668:
2663:
2662:
2658:
2648:
2605:
2604:
2600:
2590:
2565:
2512:
2511:
2507:
2490:
2457:
2456:
2452:
2424:
2390:
2389:
2385:
2341:
2340:
2336:
2308:
2267:
2266:
2262:
2227:
2226:
2222:
2194:
2166:
2165:
2161:
2151:
2149:
2119:
2118:
2114:
2086:
2068:(13): 1574–87.
2058:
2057:
2053:
2024:Nature Medicine
2017:
2016:
2009:
1975:
1974:
1970:
1942:
1922:(12): 1071–78.
1916:Lancet Oncology
1909:
1908:
1904:
1876:
1825:
1824:
1820:
1782:
1781:
1777:
1768:
1767:
1763:
1750:
1749:
1734:
1724:
1722:
1717:
1716:
1712:
1702:
1700:
1692:
1691:
1687:
1677:
1675:
1662:
1661:
1657:
1648:
1647:
1643:
1634:
1633:
1629:
1619:
1617:
1612:
1611:
1607:
1597:
1595:
1590:
1589:
1585:
1575:
1573:
1572:on 12 June 2012
1564:
1563:
1559:
1549:
1547:
1534:
1533:
1529:
1519:
1517:
1512:
1511:
1507:
1497:
1496:
1492:
1482:
1480:
1475:
1474:
1470:
1453:
1447:
1446:
1442:
1433:
1432:
1425:
1416:
1415:
1411:
1402:
1401:
1397:
1387:
1385:
1376:
1375:
1371:
1362:
1361:
1357:
1347:
1345:
1340:
1339:
1335:
1325:
1323:
1318:
1317:
1313:
1303:
1301:
1295:
1294:
1290:
1273:
1267:
1266:
1262:
1253:
1252:
1248:
1235:
1234:
1230:
1214:10.1038/469139a
1186:
1185:
1181:
1168:
1167:
1163:
1153:
1151:
1142:
1141:
1137:
1107:
1106:
1102:
1092:
1091:
1074:
1059:
1036:
1035:
1031:
1018:
1017:
1013:
1004:
1003:
999:
990:
989:
985:
980:. 5 April 2016.
976:
975:
971:
961:
959:
950:
949:
945:
936:
935:
931:
921:
919:
910:
909:
905:
896:
895:
891:
881:
879:
874:
873:
866:
856:
854:
845:
844:
840:
831:
830:
826:
812:
811:
807:
797:
795:
786:
785:
781:
768:
767:
763:
753:
751:
742:
741:
734:
725:
724:
720:
707:
706:
699:
689:
687:
678:
677:
668:
658:
656:
647:
646:
642:
632:
630:
625:
624:
620:
610:
608:
599:
598:
594:
584:
583:
572:
562:
560:
543:
542:
538:
510:
509:
500:
490:
489:
485:
480:
468:
447:
404:Nature Medicine
354:Nature Medicine
350:Nature Medicine
332:Nature Medicine
322:Nature Medicine
289:
276:
226:the research."
209:medical license
186:
170:
157:
122:Rhodes Scholars
79:
64:Duke University
44:
32:Duke University
24:Duke University
17:
12:
11:
5:
3011:
3009:
3001:
3000:
2995:
2990:
2985:
2980:
2975:
2970:
2965:
2960:
2955:
2950:
2940:
2939:
2934:
2933:
2890:
2868:
2841:
2805:
2744:
2678:
2656:
2598:
2505:
2450:
2383:
2334:
2280:(4): 1391–96.
2260:
2220:
2176:(28): 4350–7.
2159:
2112:
2051:
2007:
1968:
1902:
1818:
1775:
1761:
1732:
1710:
1685:
1655:
1641:
1627:
1605:
1583:
1557:
1527:
1505:
1490:
1468:
1440:
1423:
1409:
1395:
1369:
1355:
1333:
1311:
1288:
1260:
1246:
1243:Duke Chronicle
1228:
1179:
1176:Duke Chronicle
1161:
1135:
1116:. Nature.com.
1100:
1072:
1057:
1049:10.17226/13297
1029:
1011:
997:
983:
969:
958:on 5 July 2017
943:
929:
903:
889:
864:
838:
824:
805:
779:
776:Duke Chronicle
761:
732:
718:
715:Duke Chronicle
697:
666:
640:
618:
592:
570:
536:
498:
482:
481:
479:
476:
475:
474:
467:
464:
463:
462:
451:
446:
443:
442:
441:
432:
429:
421:
418:
410:
407:
394:
391:
382:
379:
372:
369:
360:
357:
338:
335:
328:
325:
310:
307:
296:
288:
285:
275:
272:
216:South Carolina
185:
182:
169:
166:
156:
153:
78:
75:
43:
40:
15:
13:
10:
9:
6:
4:
3:
2:
3010:
2999:
2996:
2994:
2991:
2989:
2986:
2984:
2981:
2979:
2976:
2974:
2971:
2969:
2966:
2964:
2961:
2959:
2956:
2954:
2953:Living people
2951:
2949:
2946:
2945:
2943:
2929:
2925:
2921:
2917:
2913:
2909:
2906:(6): 535–43.
2905:
2901:
2894:
2891:
2878:
2872:
2869:
2864:
2860:
2856:
2852:
2845:
2842:
2837:
2833:
2829:
2825:
2821:
2817:
2809:
2806:
2801:
2800:
2795:
2791:
2787:
2783:
2776:
2772:
2768:
2764:
2760:
2756:
2748:
2745:
2740:
2739:
2734:
2730:
2726:
2722:
2715:
2711:
2706:
2701:
2698:(5): 517–25.
2697:
2693:
2689:
2682:
2679:
2666:
2660:
2657:
2652:
2645:
2641:
2636:
2631:
2626:
2621:
2617:
2613:
2609:
2602:
2599:
2594:
2587:
2586:
2581:
2577:
2573:
2569:
2562:
2558:
2553:
2548:
2543:
2538:
2534:
2530:
2526:
2522:
2521:
2516:
2509:
2506:
2501:
2495:
2487:
2483:
2478:
2473:
2469:
2465:
2461:
2454:
2451:
2446:
2445:
2440:
2436:
2432:
2428:
2421:
2417:
2412:
2407:
2404:(6): 570–80.
2403:
2399:
2395:
2387:
2384:
2379:
2375:
2370:
2365:
2361:
2357:
2353:
2349:
2345:
2338:
2335:
2330:
2329:
2324:
2320:
2316:
2312:
2305:
2301:
2296:
2291:
2287:
2283:
2279:
2275:
2271:
2264:
2261:
2256:
2252:
2247:
2242:
2238:
2234:
2230:
2224:
2221:
2216:
2215:
2210:
2206:
2202:
2198:
2191:
2187:
2183:
2179:
2175:
2171:
2163:
2160:
2148:
2144:
2140:
2136:
2132:
2128:
2124:
2116:
2113:
2108:
2107:
2102:
2098:
2094:
2090:
2083:
2079:
2075:
2071:
2067:
2063:
2055:
2052:
2047:
2043:
2038:
2033:
2029:
2025:
2021:
2014:
2012:
2008:
2003:
1999:
1995:
1991:
1987:
1983:
1979:
1972:
1969:
1964:
1963:
1958:
1954:
1950:
1946:
1939:
1935:
1930:
1925:
1921:
1917:
1913:
1906:
1903:
1898:
1897:
1892:
1888:
1884:
1880:
1873:
1869:
1864:
1859:
1854:
1849:
1845:
1841:
1837:
1833:
1829:
1822:
1819:
1814:
1810:
1806:
1802:
1798:
1794:
1791:(6): 535–43.
1790:
1786:
1779:
1776:
1771:
1765:
1762:
1757:
1753:
1747:
1745:
1743:
1741:
1739:
1737:
1733:
1720:
1714:
1711:
1699:
1695:
1689:
1686:
1673:
1669:
1668:The Chronicle
1665:
1659:
1656:
1651:
1645:
1642:
1637:
1631:
1628:
1615:
1609:
1606:
1593:
1587:
1584:
1571:
1567:
1561:
1558:
1545:
1541:
1537:
1531:
1528:
1515:
1509:
1506:
1501:
1494:
1491:
1478:
1472:
1469:
1464:
1458:
1450:
1444:
1441:
1436:
1430:
1428:
1424:
1419:
1413:
1410:
1405:
1399:
1396:
1383:
1379:
1373:
1370:
1365:
1359:
1356:
1343:
1337:
1334:
1321:
1315:
1312:
1299:
1292:
1289:
1284:
1278:
1270:
1264:
1261:
1256:
1250:
1247:
1244:
1238:
1232:
1229:
1224:
1220:
1215:
1210:
1206:
1202:
1198:
1194:
1190:
1183:
1180:
1177:
1171:
1165:
1162:
1150:
1146:
1139:
1136:
1131:
1127:
1123:
1119:
1115:
1111:
1104:
1101:
1096:
1089:
1087:
1085:
1083:
1081:
1079:
1077:
1073:
1068:
1064:
1060:
1054:
1050:
1046:
1042:
1041:
1033:
1030:
1025:
1024:The Economist
1021:
1015:
1012:
1007:
1001:
998:
993:
987:
984:
979:
973:
970:
957:
953:
947:
944:
939:
933:
930:
917:
913:
907:
904:
899:
893:
890:
877:
871:
869:
865:
852:
848:
842:
839:
834:
828:
825:
820:
816:
809:
806:
794:
790:
783:
780:
777:
771:
765:
762:
750:
746:
739:
737:
733:
728:
722:
719:
716:
710:
704:
702:
698:
685:
681:
675:
673:
671:
667:
654:
650:
644:
641:
628:
622:
619:
606:
602:
596:
593:
587:
581:
579:
577:
575:
571:
557:
552:
551:
550:The Economist
546:
540:
537:
533:
529:
523:
519:
518:
513:
507:
505:
503:
499:
494:
487:
484:
477:
473:
470:
469:
465:
460:
456:
452:
449:
448:
444:
439:
438:
433:
430:
426:
422:
419:
415:
411:
408:
405:
401:
400:
395:
392:
389:
388:
383:
380:
377:
373:
370:
367:
366:
361:
358:
355:
351:
347:
343:
339:
336:
333:
329:
326:
323:
319:
318:breast cancer
315:
311:
308:
305:
301:
297:
294:
293:
292:
286:
284:
280:
271:
269:
265:
261:
257:
252:
250:
245:
243:
239:
235:
231:
230:Robert Califf
227:
223:
221:
217:
212:
210:
205:
203:
199:
194:
191:
183:
181:
179:
175:
168:Investigation
167:
165:
163:
154:
152:
150:
149:
144:
142:
138:
134:
130:
125:
123:
119:
115:
111:
107:
106:bioinformatic
103:
99:
94:
92:
88:
84:
76:
74:
71:
67:
65:
61:
57:
53:
49:
41:
39:
37:
33:
29:
25:
21:
2903:
2899:
2893:
2881:. Retrieved
2871:
2854:
2850:
2844:
2819:
2815:
2808:
2798:
2796:,
2758:
2754:
2747:
2737:
2735:,
2695:
2691:
2681:
2669:. Retrieved
2659:
2615:
2611:
2601:
2584:
2582:,
2527:(4): e1908.
2524:
2518:
2508:
2494:cite journal
2470:(12): 1176.
2467:
2463:
2453:
2443:
2441:,
2401:
2397:
2386:
2354:(16): 4497.
2351:
2347:
2337:
2327:
2325:,
2277:
2273:
2263:
2236:
2232:
2223:
2213:
2211:,
2173:
2169:
2162:
2150:. Retrieved
2130:
2126:
2115:
2105:
2103:,
2065:
2061:
2054:
2027:
2023:
1985:
1981:
1971:
1961:
1959:,
1919:
1915:
1905:
1895:
1893:,
1835:
1831:
1821:
1788:
1784:
1778:
1764:
1723:. Retrieved
1713:
1701:. Retrieved
1688:
1676:. Retrieved
1672:the original
1667:
1658:
1644:
1630:
1618:. Retrieved
1608:
1596:. Retrieved
1586:
1574:. Retrieved
1570:the original
1560:
1548:. Retrieved
1539:
1530:
1518:. Retrieved
1508:
1493:
1481:. Retrieved
1471:
1443:
1412:
1398:
1386:. Retrieved
1382:the original
1372:
1358:
1346:. Retrieved
1336:
1324:. Retrieved
1314:
1302:. Retrieved
1291:
1263:
1249:
1242:
1231:
1196:
1192:
1182:
1175:
1164:
1152:. Retrieved
1148:
1138:
1113:
1103:
1039:
1032:
1023:
1014:
1000:
986:
972:
960:. Retrieved
956:the original
946:
932:
920:. Retrieved
916:the original
906:
892:
880:. Retrieved
855:. Retrieved
851:the original
841:
827:
818:
808:
796:. Retrieved
792:
782:
775:
764:
752:. Retrieved
748:
721:
714:
688:. Retrieved
684:the original
657:. Retrieved
652:
643:
631:. Retrieved
621:
609:. Retrieved
604:
601:"About CCND"
595:
561:. Retrieved
556:the original
548:
539:
527:
522:the original
515:
486:
458:
454:
435:
424:
417:retractions.
413:
403:
397:
385:
375:
363:
353:
349:
345:
341:
331:
321:
313:
304:colon cancer
299:
290:
281:
277:
253:
246:
233:
228:
224:
213:
206:
195:
187:
171:
158:
146:
145:
126:
95:
80:
72:
68:
45:
28:oncogenomics
19:
18:
2948:1972 births
2822:(6): 1818.
1754:. Iom.edu.
1725:22 November
1698:ArsTechnica
1598:26 December
1576:26 December
1550:26 December
1520:22 February
1483:26 December
1348:26 December
1304:30 December
1114:Nature News
1043:. Iom.edu.
962:27 November
922:26 December
857:3 September
754:26 December
659:2 September
611:2 September
563:28 February
2942:Categories
2883:25 October
2152:13 January
2133:(5): 453.
2030:(1): 135.
1988:(2): 116.
798:17 January
690:16 January
633:25 October
528:60 Minutes
478:References
268:Automattic
148:60 Minutes
135:; and the
98:microarray
56:hematology
20:Anil Potti
2168:cancer".
1620:8 January
1326:8 January
1154:9 January
1130:211729870
258:received
256:WordPress
242:retracted
184:Aftermath
42:Biography
2928:36212758
2920:20145230
2836:22355011
2794:22355011
2775:19996213
2733:22451975
2714:17290060
2644:21912632
2612:PLOS ONE
2580:21912632
2561:18382681
2520:PLOS One
2486:21366430
2439:21366430
2420:16899777
2378:21856862
2323:21856862
2304:16263789
2255:21148129
2209:21148129
2190:17906199
2147:22228686
2101:22228686
2082:18387932
2046:21217686
2002:21277543
1957:21277543
1938:18024211
1891:21969600
1872:19050079
1813:36212758
1805:20145230
1756:Archived
1544:Archived
1540:ABC News
1457:cite web
1388:20 March
1277:cite web
1223:21228842
1067:24872966
517:CBS News
466:See also
399:PLOS One
60:oncology
2635:3166342
2552:2270912
2529:Bibcode
2369:4507035
2295:1895419
1863:2592987
1840:Bibcode
1703:11 June
1201:Bibcode
234:Science
2926:
2918:
2834:
2792:
2788:,
2773:
2731:
2727:,
2712:
2671:6 July
2642:
2632:
2578:
2574:,
2559:
2549:
2484:
2437:
2433:,
2418:
2376:
2366:
2321:
2317:,
2302:
2292:
2253:
2207:
2203:,
2188:
2145:
2099:
2095:,
2080:
2044:
2000:
1955:
1951:,
1936:
1889:
1885:,
1870:
1860:
1811:
1803:
1678:22 May
1221:
1193:Nature
1128:
1065:
1055:
882:9 June
131:; the
2924:S2CID
2851:Chest
2618:(9).
2348:Blood
2274:Blood
1809:S2CID
1126:S2CID
437:Chest
376:Blood
220:Loris
2916:PMID
2900:JAMA
2885:2018
2832:PMID
2790:PMID
2771:PMID
2729:PMID
2710:PMID
2673:2017
2640:PMID
2576:PMID
2557:PMID
2500:link
2482:PMID
2435:PMID
2416:PMID
2374:PMID
2319:PMID
2300:PMID
2251:PMID
2205:PMID
2186:PMID
2154:2012
2143:PMID
2127:JAMA
2097:PMID
2078:PMID
2062:JAMA
2042:PMID
1998:PMID
1953:PMID
1934:PMID
1887:PMID
1868:PMID
1801:PMID
1785:JAMA
1727:2013
1705:2013
1680:2017
1622:2012
1600:2011
1578:2011
1552:2011
1522:2012
1485:2011
1463:link
1390:2012
1350:2011
1328:2012
1306:2011
1283:link
1219:PMID
1156:2012
1063:PMID
1053:ISBN
964:2017
924:2011
884:2017
859:2016
800:2012
756:2011
692:2012
661:2024
635:2018
613:2024
565:2023
459:JAMA
342:JAMA
300:PNAS
262:for
58:and
2908:doi
2904:303
2859:doi
2855:142
2824:doi
2782:doi
2763:doi
2721:doi
2700:doi
2630:PMC
2620:doi
2568:doi
2547:PMC
2537:doi
2472:doi
2468:364
2427:doi
2406:doi
2402:355
2364:PMC
2356:doi
2352:118
2311:doi
2290:PMC
2282:doi
2278:107
2241:doi
2197:doi
2178:doi
2135:doi
2131:307
2089:doi
2070:doi
2066:299
2032:doi
1990:doi
1945:doi
1924:doi
1879:doi
1858:PMC
1848:doi
1836:105
1793:doi
1789:303
1209:doi
1197:469
1118:doi
1045:doi
532:CBS
62:at
2944::
2922:.
2914:.
2902:.
2853:.
2830:.
2820:18
2818:.
2769:.
2759:15
2757:.
2708:.
2696:25
2694:.
2690:.
2638:.
2628:.
2614:.
2610:.
2555:.
2545:.
2535:.
2523:.
2517:.
2496:}}
2492:{{
2480:.
2466:.
2462:.
2414:.
2400:.
2396:.
2372:.
2362:.
2350:.
2346:.
2298:.
2288:.
2276:.
2272:.
2249:.
2237:28
2235:.
2231:.
2184:.
2174:25
2172:.
2141:.
2129:.
2125:.
2076:.
2064:.
2040:.
2028:17
2026:.
2022:.
2010:^
1996:.
1986:12
1984:.
1980:.
1932:.
1918:.
1914:.
1866:.
1856:.
1846:.
1834:.
1830:.
1807:.
1799:.
1787:.
1735:^
1696:.
1666:.
1538:.
1459:}}
1455:{{
1426:^
1279:}}
1275:{{
1241:,
1217:.
1207:.
1195:.
1191:.
1174:,
1147:.
1124:.
1112:.
1075:^
1061:.
1051:.
1022:.
867:^
817:.
791:.
774:,
747:.
735:^
713:,
700:^
669:^
651:.
603:.
573:^
547:.
530:,
526:,
514:.
501:^
244:.
143:.
66:.
2930:.
2910::
2887:.
2865:.
2861::
2838:.
2826::
2802:)
2784::
2777:.
2765::
2741:)
2723::
2716:.
2702::
2675:.
2646:.
2622::
2616:6
2588:)
2570::
2563:.
2539::
2531::
2525:3
2502:)
2488:.
2474::
2447:)
2429::
2422:.
2408::
2380:.
2358::
2331:)
2313::
2306:.
2284::
2257:.
2243::
2217:)
2199::
2192:.
2180::
2156:.
2137::
2109:)
2091::
2084:.
2072::
2048:.
2034::
2004:.
1992::
1965:)
1947::
1940:.
1926::
1920:8
1899:)
1881::
1874:.
1850::
1842::
1815:.
1795::
1729:.
1707:.
1682:.
1624:.
1602:.
1580:.
1554:.
1524:.
1502:.
1487:.
1465:)
1392:.
1352:.
1330:.
1308:.
1285:)
1257:.
1239:.
1225:.
1211::
1203::
1172:.
1158:.
1132:.
1120::
1069:.
1047::
994:.
966:.
926:.
886:.
861:.
821:.
802:.
772:.
758:.
711:.
694:.
663:.
637:.
615:.
567:.
457:(
344:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.